VRAX
Virax Biolabs Group Limited (VRAX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (F). The rating has held at C for 13 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.1) | C+ (2.5) | C- (2.1) | F (0.6) | C+ (2.6) | C (2.2) |
| 2026-11-08 | B- (3.1) | C+ (2.5) | C- (2.1) | F (0.6) | C+ (2.6) | C (2.2) |
| 2026-11-01 | B- (2.9) | C+ (2.5) | C (2.2) | D- (1.0) | C+ (2.7) | C (2.3) |
| 2026-10-25 | B- (2.9) | C+ (2.5) | C (2.2) | D- (0.8) | C+ (2.6) | C (2.2) |
| 2026-10-18 | B- (2.9) | C+ (2.5) | C (2.2) | D- (0.9) | C+ (2.6) | C (2.2) |